OPXA Share Price

Open 0.84 Change Price %
High 0.83 1 Day -0.01 -1.22
Low 0.80 1 Week -0.07 -7.95
Close 0.81 1 Month -0.16 -16.49
Volume 65028 1 Year -1.35 -62.50
52 Week High 4.93
52 Week Low 0.50
OPXA Important Levels
Resistance 2 0.84
Resistance 1 0.83
Pivot 0.81
Support 1 0.79
Support 2 0.78
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
FTR 1.94 -8.06%
FTR 1.94 -8.06%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 26.47 1.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
LLEN 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HAUP 0.06 20.00%
FALC 0.36 16.13%
OTIV 1.70 15.65%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

OPXA Technical Analysis 5
As on 23rd Mar 2017 OPXA Share Price closed @ 0.81 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.42 & Strong Sell for SHORT-TERM with Stoploss of 0.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
OPXA Target for March
1st Target up-side 1.13
2nd Target up-side 1.26
3rd Target up-side 1.38
1st Target down-side 0.77
2nd Target down-side 0.64
3rd Target down-side 0.52
OPXA Other Details
Segment EQ
Market Capital 14797129.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.opexatherapeutics.com
OPXA Address
OPXA
2635 Technology Forest Boulevard
The Woodlands, TX 77381
United States
Phone: 281-272-9331
Fax: 281-872-8585
OPXA Latest News
Interactive Technical Analysis Chart Opexa Therapeutics, Inc. ( OPXA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Opexa Therapeutics, Inc.
OPXA Business Profile
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.